Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Scientists predicted remdesivir’s success with a simulation. Here’s how.

Cesar Padilla, MD
Meds
May 7, 2020
Share
Tweet
Share

In 2002 pro baseball manager Billy Beane accomplished the impossible. He took the Oakland Athletics, a low-budget team comprised of unknown baseball players to the playoffs. The story’s magic is that he was able to compete with the Goliaths of the baseball world – the New York Yankees – with only a fraction of the budget. The idea is simple – draft players who are statistically successful in their respective positions, no matter their unorthodox or individual quirks. Beane’s secret was hiring baseball outsider Peter Brand, a recently minted economics graduate who would introduce Beane to these statistical strategies. Their use of statistics marks a seismic shift in sports history (and even business), Beane and Brands’ method is now standard for most professional sports teams. Every few years, a group of “nobodies,” engineered on analytics, shocks the “old guard.” Think three-time champion Steph Curry and the Golden State Warriors.

Its revenge of the nerds for sports.

The world of medicine – it’s therapeutics and research – resembles analytics in sports. As an ICU physician, one of the greatest experiences I can share with students is the ability to use “evidence-based medicine,” statistically and rigorously studied treatments, to save patients’ lives. When properly conducted, scientific evidence cuts viciously through the establishment of tyranny, corruption, and falsehoods. A well-designed study can dethrone years of conventional, yet unproven practices.

In February, a laboratory in Taiwan “Moneyballed” their way to success against COVID-19, predicting potential treatments against the virus. During the 2003 SARS outbreak, surrounding countries like Taiwan were left on their own to defend themselves. The World Health Organization (WHO) largely ignored Taiwan’s plea for help researching the virus. China does not recognize the government of Taiwan as a sovereign territory, and the World Health Organization does not recognize Taiwan as an official member.

Once again, the Yankees were not playing fair with the smaller teams.

Almost 20 years after SARS, Taiwanese scientists wasted no time and used a novel tool, 3D simulation, to research therapeutics against COVID-19. The capacity of 3D molecular imaging gives scientists the ability to create images of viruses and therapeutics based on 2-D data. Think Jurassic Park – virtual dinosaur creation – via DNA building. Once these images are created, scientists can then “simulate” what happens when a virus meets a particular medication. The exact molecular mimicry – the shape and curves of viruses and drug structures – are incredibly precise. Shortly after the outbreak, the COVID-19 genetic code was quickly hacked by scientists, making virtual creation possible.

Building upon the limited (in-vitro) data implying HIV antivirals efficacy against SARS, the decision was made to simulate the efficacy of these medications (along with other antivirals) against the COVID-19 virtual structure. Using simulation programs, the scientists now had a total of 10 HIV antivirals and four other antivirals to test. Two antivirals they were testing – remdesivir and favipiravir – are “nucleotide analogue” antivirals which had previously shown modest effect against the Ebola virus.

The stage was set for simulation. Each of the 14 antivirals would run through a simulation 100 times. In the end, the scientists would map out the precision of drug to virus binding. An image is then created – a sort of heat map, or bullseye blueprint, showing how well the drug binds to the virus. The results, published February 17, showed that most antivirals attacked the virus with mild to moderate efficacy (as predicted by the 2003 SARS data). Remdesivir – the nucleotide analogue and Ebola medication – stood out as an optimal match. The virtual simulations predicted remdesivir as a perfect match for COVID-19. In the authors’ words:

… When we tested the active form (CHEMBL2016761) of remdesivir, the docking site revealed a perfect dock in the overlapping region of the NTP binding motif. This result suggests that remdesivir could be a potential therapeutic agent. Clinical trials still must be done in order to confirm the curative effect of these drugs.

On January 31, the first confirmed patient in the U.S. with COVID-19 is successfully treated with remdesivir. In the following weeks, several other reports of clinical improvement in patients receiving remdesivir are published. On April 10, the New England Journal of Medicine publishes a series of patients treated with remdesivir and shows that 68 percent showed clinical improvement.

On April 29, based on the results of an international, randomized placebo-controlled trial of 1063 patients, the FDA announced plans for emergency authorization use of remdesivir. Patients receiving remdesivir recovered 31 percent faster compared to those receiving a placebo. Although the differences in mortality did not approach statistical significance, there was a trend for improvement in survival in the remdesivir group (8 percent vs. 11 percent). A separate randomized trial showing no improvement with remdesivir was published in the Lancet on April 23. This study has been criticized for lacking statistical power (the study enrolled 237 of intended 453).

Although the study Dr. Fauci is citing is yet to be published, an international monitoring group verified the results of the study’s analysis. Based on these results, Dr. Fauci announced remdesivir would be considered the standard of care – medicine’s medicolegal term for optimal treatment of action, given the currently available treatment options. Standard of care is defined as a “… diagnostic and treatment process that a clinician should follow for a certain type of patient, illness, or clinical circumstance.”

Favipiravir (also a nucleotide analog and Ebola antiviral), which showed modest binding efficacy in these simulations, is currently in phase III trials for COVID-19 in Japan. Given the promising results for remdesivir, will the simulations performed in Taiwan prove to be the future of therapeutics in medicine? Will our response to future pandemics be based on the simulation?

ADVERTISEMENT

In the words of Sun Tzu, one of the greatest military strategists in history, “If you know the enemy and know yourself, you need not fear the result of a hundred battles.” If we can simulate the results of 100 battles, we should not fear the results or the strength of our enemy.

That’s a sports bet worth taking.

Cesar Padilla is an obstetric anesthesiologist and can be reached on Twitter @themillennialmd and on Instagram @doctor_cesar_.

Image credit: Shutterstock.com

Prev

A reflection on a man's life before dissection

May 7, 2020 Kevin 0
…
Next

Has your physician persona crowded out other aspects of yourself?

May 7, 2020 Kevin 2
…

Tagged as: COVID, Infectious Disease, Medications

Post navigation

< Previous Post
A reflection on a man's life before dissection
Next Post >
Has your physician persona crowded out other aspects of yourself?

ADVERTISEMENT

More by Cesar Padilla, MD

  • National Latino Physician Day: a crisis sparked the origin of a national day

    Cesar Padilla, MD & Michael G. Galvez, MD
  • Our foundation as a nation and the care for the sick, poor, and injured are inextricably linked

    Cesar Padilla, MD
  • A doctor’s poem as an intensivist and obstetric anesthesiologist

    Cesar Padilla, MD

Related Posts

  • Why remdesivir may not be a wonder drug

    Daniel Hopkins, MD
  • Are there reasons to doubt remdesivir?

    Daniel Hopkins, MD
  • Vaping likely has dangers that could take years for scientists to even know about

    Ilona Jaspers, PhD
  • CMS risks ACO success by forcing move to another track

    Manish Naik, MD
  • To raise future scientists, address our innate curiosity  

    Jason J. Han, MD
  • 5 tips to medical resident success

    Lisa Sieczkowski, MD

More in Meds

  • FDA delays could end vital treatment for rare disease patients

    G. van Londen, MD
  • Pharmacists are key to expanding Medicaid access to digital therapeutics

    Amanda Matter
  • How medicine repurposing enables value-based pain management and insomnia therapy

    Olumuyiwa Bamgbade, MD
  • Forced voicemail and diagnosis codes are endangering patient access to medications

    Arthur Lazarus, MD, MBA
  • From stigma to science: Rethinking the U.S. drug scheduling system

    Artin Asadipooya
  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Beyond burnout: Understanding the triangle of exhaustion [PODCAST]

      The Podcast by KevinMD | Podcast
    • Facing terminal cancer as a doctor and mother

      Kelly Curtin-Hallinan, DO | Conditions
    • Online eye exams spark legal battle over health care access

      Joshua Windham, JD and Daryl James | Policy
    • FDA delays could end vital treatment for rare disease patients

      G. van Londen, MD | Meds
    • Pharmacists are key to expanding Medicaid access to digital therapeutics

      Amanda Matter | Meds
    • Why ADHD in women requires a new approach [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Beyond burnout: Understanding the triangle of exhaustion [PODCAST]

      The Podcast by KevinMD | Podcast
    • Facing terminal cancer as a doctor and mother

      Kelly Curtin-Hallinan, DO | Conditions
    • Online eye exams spark legal battle over health care access

      Joshua Windham, JD and Daryl James | Policy
    • FDA delays could end vital treatment for rare disease patients

      G. van Londen, MD | Meds
    • Pharmacists are key to expanding Medicaid access to digital therapeutics

      Amanda Matter | Meds
    • Why ADHD in women requires a new approach [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...